Platelets release vasoactive substances that may contribute to augmented vasoconstriction. In this study, we examined vascular responses to activation of platelets in vivo by infusion of collagen. Purified bovine collagen was infused into the blood-perfused hind limb of normal and atherosclerotic cynomolgus monkeys. Resistance of the total limb and large arteries was measured at constant flow. In normal monkeys, collagen produced a decrease in total limb resistance, with a modest constrictor response of the large arteries. In atherosclerotic monkeys, collagen produced a transient, small decrease in total limb resistance, with pronounced constriction of large arteries. Indomethacin (5 mg/kg i.v.) and the thromboxane Aj/prostaglandin H 2 receptor antagonist SQ29,548 (2 mg/kg i.v.) virtually abolished the large-artery constrictor response to collagen in atherosclerotic monkeys. The 5-HT 2 -serotonergic receptor antagonist ketanserin (0.6 mg/kg i.v.) had no effect on the vasoconstrictor response. We conclude that 1) large arteries constrict and small vessels dilate in response to collagenmediated activation of platelets in vivo in normal and atherosclerotic monkeys, 2) large-artery constriction in response to activation of platelets is augmented in atherosclerotic monkeys, and 3) the augmented large-artery constriction in atherosclerotic monkeys may be mediated primarily by thromboxane. The findings provide evidence that platelets may contribute to augmented constrictor responses of atherosclerotic arteries. (Arteriosclerosis and Thrombosis 1991;11:1745-1751)
sponses is evidence that activation of platelets can produce vasoconstriction. Transient reductions in blood flow (cyclic flow variation) have been demonstrated in a canine preparation of severe coronary artery stenosis with endothelial damage. 8 Reductions in flow result from intracoronary deposition of platelets that may trigger vasoconstriction, largely mediated by TxA 2 , serotonin, 9 and ADP 10 that are released by activated platelets. It is not clear, however, whether reductions in flow are mediated by mechanical obstruction by aggregated platelets, 11 or whether platelet-induced vasoconstriction may contribute to reductions in blood flow.
In a previous study, we found that activation of platelets in vitro, with rapid injection of vasoactive products that are released by platelets, failed to produce vasoconstriction in either normal or atherosclerotic monkeys. 12 We are not aware of direct evidence that activation of platelets in vivo produces constriction in atherosclerotic vessels.
In the present study, we examined vascular responses to activation of platelets by infusion of purified bovine collagen directly into the iliac artery of normal and atherosclerotic monkeys. Collagen is a potent activator of platelets in vivo. 13 - 14 We anticipated that activated platelets would produce vasodi-latation in normal monkeys and impaired vasodilatation or vasoconstriction in atherosclerotic monkeys. To clarify the mechanisms of these vascular responses, experiments were also performed in atherosclerotic monkeys after administration of 1) indomethacin, 2) the TxA^prostaglandin H 2 (TxAP GH 2 ) receptor antagonist SQ29,548, and 3) the 5-HT 2 -serotonergic receptor antagonist ketanserin.
Methods

Animal Groups
Two groups of adult male Malaysian monkeys were studied. Nineteen monkeys (normal group) were fed a normal diet (Purina Monkey Chow, Ralston Purina, Richmond, Ind.). Eighteen monkeys (atherosclerotic group) were fed an atherogenic diet, which contained cholesterol (1 mg/cal) and 43% of total calories as fat for 19 ±2 months (mean±SEM). The normal monkeys weighed 6.6 ±1.1 kg, and atherosclerotic monkeys weighed 6.0±1.4 kg. At intervals of 3-4 months, the monkeys were sedated with ketamine hydrochloride (10 mg/kg i.m.), and a venous blood sample was obtained. Total plasma cholesterol and triglyceride were determined as described previously. 15 
Hemodynamic Studies
At the time of the study, monkeys were sedated with ketamine hydrochloride (15 mg/kg i.m.) and anesthetized with chloralose (100 mg/kg i.v.). A tracheostomy was performed, and monkeys were intubated and ventilated with room air and supplemental oxygen. Gallamine triethiodide (5 mg/kg i.v.) was administered for paralysis of skeletal muscles, and heparin sodium (500 units/kg i.v.) was given for anticoagulation. Arterial blood gases and pH were monitored during each study and maintained at normal levels by adjustment of the ventilatory rate and tidal volume, or by intravenous injection of small amounts of sodium bicarbonate. Rectal temperature was maintained at 37-38°C with a heating pad.
A polyethylene catheter was inserted into the right brachial artery to measure aortic pressure and to obtain blood samples. Catheters were also inserted into both brachial veins for injection of fluids and drugs.
Through a laparotomy, the bifurcation of the abdominal aorta and the proximal left iliac artery was exposed, isolated, and cannulated with perfusion tubing. A catheter was also inserted into the left iliac vein for collection of blood samples. The left dorsal pedal artery was exposed, and a PE-50 catheter was inserted retrogradely to measure pressure. A calibrated Harvard Model 1210 pulsatile perfusion pump (Harvard Instruments, South Natick, Mass.) was used to perfuse the left iliac artery at constant flow with blood from the abdominal aorta, and iliac perfusion pressure was measured continuously. When the pump was stopped, perfusion pressure decreased rapidly to 10-15 mm Hg, which indicated that vascular isolation was adequate. Baseline perfusion pressure of the hind limb was established by adjusting blood flow so that perfusion pressure was similar to mean systemic arterial pressure; flow was then kept constant.
Total limb resistance (TLR) was calculated from the equation TLR=iliac perfusion pressure (millimeters of mercury) divided by hind limb blood flow (milliliters per minute). The difference between iliac perfusion pressure and dorsal pedal pressure, at constant flow, denoted the resistance of large arteries in the limb. We have previously described the method in detail.
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Experimental Protocol
We studied the vascular effects of infusion of collagen in the limb. Acid-soluble collagen (type I) from bovine tendon (Sigma Chemical Co., St. Louis, Mo.) was prepared as described previously. 18 Collagen was infused intra-arterially at a dose of 10 and 50 /ig/min for 9 minutes each. Responses of the total limb and large artery were measured throughout the period of infusion, and maximum dilator and constrictor responses were determined. Blood samples were drawn from the iliac vein of the perfused limb before and at the end of collagen infusion to measure platelet and leukocyte counts.
We also studied the vascular effects of adenosine, ADP (from equine muscle), phenylephrine, and serotonin (all from Sigma) and the TxA 2 analogue U46,619 (15 -5-hydroxy-11 a,9a-epoxymethanoprosta-5Z,13£-dieonic acid; The Upjohn Co., Kalamazoo, Mich.). Adenosine (5xl(T 8 and 5xMT 7 M), ADP (5xl0" 10 and 5xlO" 9 M), phenylephrine (5xlO" 9 and 5xl0" 8 M), serotonin (5xl0" 8 M), and U46.619 (5xlO~1 0 M) were injected in random order as a 0.1-ml bolus into the iliac perfusion tubing. Injection of 0.1 ml of vehicle had no hemodynamic effects. In some experiments, hemodynamic effects of infusion of collagen and agonists were also determined after pretreatment for 30 minutes with either indomethacin (5 mg/kg i.v., Sigma), the TxA^fPGHj receptor antagonist SQ29.548 (2 mg/kg i.v., The Upjohn Co.), or the 5 -HT 2 -serotonergic receptor antagonist ketanserin (0.6 mg/kg i.v., Janssen Pharmaceutica, Piscataway, N.J.).
At the end of the experiment, the anesthetized monkeys were killed with intravenous potassium chloride. The leg was severed through the hip joint and weighed, so that limb blood flow and vascular resistance could be expressed per 100 g of limb.
Morphological Studies
Iliac and femoral arteries were removed, examined for gross lesions, and fixed by immersion in 10% buffered formalin. Specimens were taken at standardized sites from the proximal segment of the iliac artery and the middle segment of the femoral artery, as described previously. 16 - 19 Histological study was performed on paraffin-embedded transverse sections. Sections were stained with hematoxylin-eosin and Verhoeffs-van Gieson's stains. Morphometric determination of intimal area was performed with an image analyzer as described previously. 16 
Statistical Analysis
Data are presented as mean±SEM. Statistical differences between mean values were analyzed with unpaired and paired Student's t test. Statistical significance was considered as/?<0.05.
Results
Morphology and Plasma Lipids
In atherosclerotic monkeys, morphological changes were similar to those described previously. ). Plasma cholesterol was 122±4 mg/dl in normal and 632±25 mg/dl in atherosclerotic monkeys (p<0.05). Plasma triglycerides were <40 mg/dl in both groups.
Hemodynamic Studies
Baseline values. Baseline large-artery resistance was greater (/?<0.05) in atherosclerotic monkeys than in normal monkeys (Table 1) . Total limb resistance was not different in normal and atherosclerotic animals.
Responses to collagen. Infusion of collagen produced a biphasic hemodynamic response in the limb. An initial decrease in total limb resistance was noted, with minimum resistance observed during the first 2 minutes of infusion in both normal and atherosclerotic monkeys. The decrease in total limb resistance was significantly less in atherosclerotic monkeys than in normal animals during infusion of collagen (50 Values are mean±SEM. Early response is the minimum resistance measured between 1 and 2 minutes of infusion of collagen, and delayed response represents maximum resistance measured between 5 and 9 minutes of infusion of collagen. The number of monkeys is in parentheses, and change in resistance is expressed as millimeters of mercury per milliliter per minute per 100 g tissue.
*/?<0.05 vs. normal.
jig/min) ( Table 2 ). The initial decrease in total limb resistance was followed by a gradual return of resistance toward baseline in normal monkeys and a modest vasoconstriction in atherosclerotic monkeys (Table 2) . Large-artery constriction was observed during infusion of collagen in both groups of monkeys. The large-artery constrictor response was significantly augmented (Table 2) in the atherosclerotic group, with maximum resistance occurring at 5.2 ±0.9 minutes in atherosclerotic monkeys and at 6.0±0.9 minutes in normal monkeys. Constrictor responses in large arteries were sustained to the end of infusion in both groups of monkeys. To test the specificity of augmented constrictor responses to vasoactive platelet products in atherosclerotic monkeys, the effects of phenylephrine were also examined. Phenylephrine produced similar constrictor responses in normal and atherosclerotic monkeys (data not shown).
In normal monkeys, the platelet count in blood from the iliac vein decreased by 11±2% and 13±3% from a baseline count of 148±12xlO 1011 Therefore, responses to injection of ADP were examined in normal and atherosclerotic monkeys. ADP decreased total limb resistance in normal monkeys (Figure 2) , with minimal effects on the resistance of large arteries of the limb (data not shown), which indicates that dilatation was confined to small vessels. The dilator response to ADP was maximum within 2 minutes after injection. The vasodilator response to ADP was significantly impaired in atherosclerotic monkeys (Figure 2 ). 
FIGURE 2. Bar graphs showing changes in total limb resistance (mm Hg/ml/min per 100 g) after intra-arterial injection of ADP (5xlO''° M) in normal (n=13) and atherosclerotic (n=9) monkeys and adenosine (5x.lO~s M) in normal (n=12) and atherosclerotic (n=6) monkeys. Values are mean±SEM. *p<0.05 vs. normal monkeys.
To test the specificity of impaired vasodilator responses to ADP in atherosclerosis, the effects of adenosine were examined. Adenosine reduced total limb resistance in both normal and atherosclerotic monkeys ( Figure 2 ) and had minimal effects on large-artery resistance (data not shown). In contrast to ADP, the vasodilator response to adenosine was not impaired in atherosclerotic monkeys (Figure 2) .
Discussion
There are several findings in this study. First, activation of platelets by intra-arterial infusion of collagen produces a biphasic response, with an initial decrease in total limb resistance in both normal and atherosclerotic monkeys, followed by a gradual return of resistance toward baseline in normal monkeys and a modest vasoconstriction in atherosclerotic monkeys. Second, the initial vasodilator response to collagen is significantly reduced in atherosclerotic monkeys. Third, activation of platelets by infusion of collagen produces pronounced constriction of large arteries in atherosclerotic monkeys, and this vasoconstrictor effect appears to be mediated primarily by TxA 2 .
Activation of Platelets In Vivo
Platelet activation and aggregation may be induced by several humoral or hemodynamic stimuli or by interaction with the vessel wall.
14 Platelets do not attach to the intact endothelium, but they adhere to a disrupted or damaged endothelial surface.
22
- 23 Collagen in the exposed subendothelial matrix of ulcerated atherosclerotic plaques markedly stimulates platelet adhesion and activation. 24 Collagen was chosen to activate platelets in the present study because it does not appear to produce any direct vascular responses.
Several findings suggest that vascular responses to collagen in this model are mediated by activation of platelets and release of vasoactive products. Venous platelet counts decreased significantly during infusion of collagen in both normal and atherosclerotic monkeys. Collagen had no effect on the leukocyte count. These data support earlier observations in other species that systemic administration of collagen reduces the platelet count and produces an increase in serotonin and prostanoid levels in plasma. i^-z? Reduction in the platelet count after infusion of collagen in this model can result from a combination of at least two mechanisms. First, adhesion of platelets to collagen microfibrils via glycoprotein-dependent processes 28 may initially reduce platelet count and induce arachidonic acid metabolism in platelets with release of intragranular products. 29 - 30 Second, endogenous mediators of platelet activation, such as ADP, serotonin, TxA 2 , and prostaglandin endoperoxides released by the initial collagen-induced activation of platelets, may propagate the activation process and further reduce the platelet count. The finding that infusion of collagen produced an initial vasodilatation followed by delayed vasoconstriction may reflect this sequential augmentation of platelet activation.
Collagen has no direct vascular effects at the doses used to activate platelets in this model. We have observed that doses of collagen from 1 to 100 /xg/ml fail to produce a response in femoral arteries in vitro in both normal and atherosclerotic monkeys. Thus, there is substantial evidence that responses to collagen in this experimental model are mediated via activation of platelets.
Limitations
Collagen was infused intra-arterially to activate platelets in vivo in this study. We did not measure platelet products to quantify platelet activation and to confirm that vascular responses were mediated by specific vasoactive products that are released by activated platelets. As summarized above, there is substantial evidence that vascular responses to collagen were mediated via vasoactive substances released from activated platelets.
Platelets from hypercholesterolemic humans are hyperaggregable and release more TxA 2 31 -33 than do platelets from normal humans. Without quantitative measurement of TxA 2 or its metabolites, it is not clear whether augmented vasoconstrictor responses to collagen in atherosclerotic monkeys were due to enhanced sensitivity of the vessel to thromboxane, as has been shown in atherosclerosis, 7 due to enhanced release of thromboxane from hypercholesterolemic platelets, or related to both mechanisms. It is also not clear whether vasoactive products were released by platelets that were activated within the circulating blood or after adherence to the vessel wall.
The decrease in circulating platelet count is used as an index of platelet activation by collagen. The maximum decrease in platelet count occurs within 1-2 minutes after injection of collagen in rabbits. 13 A decrease in venous platelet count was demonstrated during infusion of collagen in this study, but without on-line measurements of platelet count, we cannot exclude the possibility that there may have been an even greater decrease earlier during infusion.
Mechanisms of Altered Vascular Response to Activated Platelets
In arteries with intact endothelium, aggregating platelets produce relaxation that appears to be mediated by ADP. 34 - 35 In contrast, in arteries with denuded endothelium, platelets produce contraction that appears to be mediated by thromboxane and serotonin. 35 Several studies indicate that aggregation of platelets can reduce blood flow, 8 11 demonstrated a cyclic reduction in coronary blood flow in dogs caused by periodic formation of platelet aggregates at the site of endothehal injury followed by spontaneous dissolution. This cyclic flow reduction is mediated by a cyclooxygenase-dependent pathway, and active vasoconstriction did not seem to contribute to the reduction in flow because nitrogh/cerin failed to affect the cyclic reductions in blood flow. These findings were confirmed in a similar canine model, 9 with a marked reduction in coronary diameter that was mediated by TxA 2 and serotonin released by aggregated platelets at the site of endothelial injury. As in Folts' study, nitrogh/cerin and diltiazem did not affect either the cyclic flow reduction or the reduction in the arterial diameter. Lam et al 37 also demonstrated platelet-induced vasoconstriction at sites of endothelial injury in porcine carotid arteries.
All of these studies demonstrating platelet-mediated reduction in arterial diameter in vivo have been performed in experimental models after endothelial injury. We are not aware of direct evidence that activation of platelets in vivo produces constriction in atherosclerotic vessels. Aggregation of human platelets in vitro and rapid injection of the supernatant intra-arterially produced vasodilatation in normal monkeys. 12 Vasodilator responses were significantly impaired by atherosclerosis, but we were not able to demonstrate that platelet products produce vasoconstriction in atherosclerotic primates. It is possible that vasoconstrictor responses were not observed because serotonin and thromboxane, which are the vasoconstrictor products released by platelets, have a shorter half-life (60-120 seconds 39 and 30 seconds, 40 respectively) than does ADP (4 minutes 41 ).
Based on previous studies in vitro 2 -3442 - 44 and our findings in vivo, it is likely that vasodilatation in response to collagen is mediated by ADP. Dilatation in response to both ADP and activation of platelets occurs in small vessels but not in large arteries of the limb, maximal vasodilatation to both stimuli occurs within 2 minutes, and vasodilatation to both stimuli is impaired in atherosclerotic monkeys. Activation of platelets probably does not occur after intra-arterial injections of ADP because the estimated maximal local concentrations of ADP are 100-fold less than the concentrations required for activation of platelets, 45 and changes in vascular resistance are not prolonged.
Inhibition of vasoconstriction by indomethacin or SQ29,548 but not by ketanserin suggests that the vasoconstrictor response to collagen-activated platelets may be mediated primarily by TxA 2 . We cannot, however, exclude a role for the endoperoxide PGH 2 in the vasoconstrictor response to platelet activation because SQ29.548 is also a PGH 2 receptor antagonist. 46 It is also possible that serotonin contributes to the vasoconstrictor response to collagen by potentiating the effects of TxA 2 .
of vascular tone by the endothelium, but some studies have suggested that atherosclerosis may increase (not decrease) prostacyclin release. 33 Vasodilator responses to ADP, which are mediated through release of endothelium-derived relaxing factor, are attenuated in atherosclerotic arteries. 7 We have demonstrated previously that constrictor responses to serotonin and TxA 2 are augmented in atherosclerotic vessels in vivo. 4 -7 Augmented constrictor responses to serotonin and TxA 2 in atherosclerotic vessels do not reflect nonspecific change in vascular responsiveness secondary to increased baseline resistance because vasoconstrictor responses to phenylephrine, norepinephrine, and angiotensin "are not enhanced. 4 
Speculation and Implications
Platelets may contribute to augmented constriction of atherosclerotic arteries by releasing potent vasoactive substances. i-4.8A36.37 Elevated levels of TxE^ in patients with active unstable angina 55 and increased levels of TxB2 and its metabolites, platelet-specific protein /3-thromboglobulin, and the platelet aggregate ratio in patients with peripheral vascular disease 33 provide evidence that platelet activation may occur in vivo in human atherosclerosis. This study provides direct evidence that activation of platelets can produce constriction in vivo in atherosclerotic arteries. The findings are compatible with the hypothesis 1 -4 that endothelial dysfunction produced by atherosclerosis, with platelet aggregation and activation, in conjunction with platelet-induced vasoconstriction, may contribute to augmented vasoconstriction or even vasospasm and ischemic events.
